MELBOURNE, March 14, 2026, 10:01 AEDT
CSL Limited fixed the Australian dollar payout for its interim dividend and continued its buyback, but those steps barely budged the mood around the biotech stock. Shares finished Friday at A$141.03, not far from the 52-week low of A$139.22 hit earlier in the session.
Investors are weighing whether February’s steep profit miss and the sudden CEO departure signal a bottom—or something more drawn out. CSL has dropped 43.6% in the past year, following an 81% plunge in first-half earnings. The company blamed soft plasma and vaccine sales, one-offs, and Paul McKenzie’s abrupt exit at the top. Shares slid to lows not seen since 2018 after the announcement.
CSL picked up another 83,264 shares on Thursday, spending A$11.77 million, according to its latest buyback update. That adds to the 4,233,728 shares already scooped up before Thursday’s session as part of an on-market buyback program with a ceiling of up to US$750 million.
CSL’s separate filing pegged the interim dividend for shareholders in Australia at A$1.809829 a share, matching what was disclosed at half-year earnings. The payout lands April 9, using March 11 as the record date for eligibility.
Interim chief Gordon Naylor isn’t backing down. “I’m not prepared to accept that we can’t do better,” he told analysts in February. He pointed straight to the blood-plasma business, describing it as “where the greatest opportunity lies”. Reuters
On March 11, Morningstar’s Shane Ponraj slashed his fair value estimate for CSL by 22%, now setting it at A$210. The analyst flagged CSL’s softer plasma performance as a sign of deeper, structural issues rather than a fleeting setback. Ponraj also warned that “competitors willing to sign lower-margin contracts” could pressure CSL to adapt its approach in bidding wars. Morningstar
Ponraj outlined the competitive landscape in his note. Roche’s Hemlibra is still squeezing rival haemophilia therapies, he said. CSL, for its part, holds onto the No. 2 spot in flu vaccines, just after Sanofi.
The March 13 filings didn’t offer surprises, yet investors kept an eye on them. CSL put up 167,561 shares for quotation, each priced at A$124.56 under its employee plan, and revealed 60,048 new restricted rights. Of those, 39,579 went to Naylor, tied to the long-term incentive plan.
Shareholders face a risk: capital returns might not be enough to make up for a sluggish recovery on the operations side. Citi flagged back in February that CSL’s guidance looked tight—little margin for error, with the vaccine business Seqirus barely adding to second-half numbers, generics still dogging Vifor, and most of the burden falling on Behring to meet annual goals. The stock hasn’t come close to its A$275.79 high from the last year.
